| Title |
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, August 2014
|
| DOI | 10.1038/clpt.2014.159 |
| Pubmed ID | |
| Authors |
K E Caudle, A E Rettie, M Whirl-Carrillo, L H Smith, S Mintzer, M T M Lee, T E Klein, J T Callaghan |
| Abstract |
Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large interpatient variability, partly due to genetic variations in the gene encoding cytochrome P450 (CYP)2C9 (CYP2C9). Furthermore, the variant allele HLA-B*15:02, encoding human leukocyte antigen, is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotype (also available on PharmGKB: http://www.pharmgkb.org). The purpose of this guideline is to provide information for the interpretation of HLA-B and/or CYP2C9 genotype tests so that the results can guide dosing and/or use of phenytoin. Detailed guidelines for the use of phenytoin as well as analyses of cost-effectiveness are out of scope. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines are periodically updated at http://www.pharmgkb.org.Clinical Pharmacology & Therapeutics (2014); advance online publication 17 September 2014. doi:10.1038/clpt.2014.159. |
X Demographics
The data shown below were collected from the profiles of 14 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 36% |
| Spain | 3 | 21% |
| Argentina | 1 | 7% |
| United Kingdom | 1 | 7% |
| Canada | 1 | 7% |
| Unknown | 3 | 21% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 57% |
| Scientists | 5 | 36% |
| Practitioners (doctors, other healthcare professionals) | 1 | 7% |
Mendeley readers
The data shown below were compiled from readership statistics for 162 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Unknown | 161 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 28 | 17% |
| Researcher | 24 | 15% |
| Student > Bachelor | 18 | 11% |
| Student > Ph. D. Student | 17 | 10% |
| Student > Postgraduate | 11 | 7% |
| Other | 31 | 19% |
| Unknown | 33 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 39 | 24% |
| Pharmacology, Toxicology and Pharmaceutical Science | 39 | 24% |
| Biochemistry, Genetics and Molecular Biology | 15 | 9% |
| Agricultural and Biological Sciences | 10 | 6% |
| Nursing and Health Professions | 5 | 3% |
| Other | 15 | 9% |
| Unknown | 39 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2020.
All research outputs
#2,513,160
of 25,837,817 outputs
Outputs from Clinical Pharmacology & Therapeutics
#436
of 4,619 outputs
Outputs of similar age
#24,532
of 244,961 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#4
of 31 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,619 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 244,961 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.